Filtered By:
Condition: Chronic Kidney Disease
Procedure: Heart Transplant
Therapy: Dialysis

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis
Conclusion Our meta-analysis revealed a trend for a reduction of the risk of ischemic stroke in hemodialysis patients with AF treated with VKA. The true protective effect may have been underestimated, owing to inclusion of low-risk patients not expected to benefit from anticoagulation and to suboptimal anticoagulation. However, assessment of the overall effect of VKA in hemodialysis patients should also take into account the increased risk of bleeding, in particular of hemorrhagic stroke. Whether new oral anticoagulants provide a better benefit–risk ratio in hemodialysis patients should be the subject of future trials.
Source: American Heart Journal - October 4, 2016 Category: Cardiology Source Type: research

Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure)
Conclusion In Asian type 2 diabetic patients with chronic kidney disease and heavy proteinuria, reduction of SBP ≤ 130 mmHg was associated with greater renoprotection than cardioprotection. However, our results emphasize the need to individualize BP targets in type 2 diabetes.
Source: Nephrology Dialysis Transplantation - February 22, 2016 Category: Urology & Nephrology Authors: Imai, E., Ito, S., Haneda, M., Harada, A., Kobayashi, F., Yamasaki, T., Makino, H., Chan, J. C. N. Tags: Chronic Kidney Disease Source Type: research

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
Background Blood pressure (BP) control and reduction of urinary protein excretion using agents that block the renin–angiotensin aldosterone system are the mainstay of therapy for chronic kidney disease (CKD). Research has confirmed the benefits in mild CKD, but data on angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use in advanced CKD are lacking. In the STOP-ACEi trial, we aim to confirm preliminary findings which suggest that withdrawal of ACEi/ARB treatment can stabilize or even improve renal function in patients with advanced progressive CKD. Methods The STOP-ACEi trial (tri...
Source: Nephrology Dialysis Transplantation - January 25, 2016 Category: Urology & Nephrology Authors: Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., El Nahas, M. Tags: Chronic Kidney Disease Source Type: research

Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
Conclusion The majority of deaths occurred in patients who did not experience a non-fatal CV or renal event, although the risk of death was higher following an event. Our findings illustrate continuing opportunities to reduce morbidity and mortality in patients with type 2 diabetes.
Source: European Heart Journal - September 21, 2015 Category: Cardiology Authors: Jhund, P. S., McMurray, J. J. V., Chaturvedi, N., Brunel, P., Desai, A. S., Finn, P. V., Haffner, S. M., Solomon, S. D., Weinrauch, L. A., Claggett, B. L., Pfeffer, M. A. Tags: Prevention and epidemiology Source Type: research

Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis
Conclusions: Cardiovascular events and fractures were associated with lower utility scores, suggesting a perceived decrease in quality of life beyond the impact of CKD and SHPT.
Source: Health and Quality of Life Outcomes - June 30, 2015 Category: Global & Universal Authors: Evan DaviesLouis MatzaGavin WorthDavid FeenyJacqueline KostelecSteven SorokaDavid MendelssohnPhilip McFarlaneVasily Belozeroff Source Type: research

Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial
Conclusions Two 750-mg infusions of FCM are a safe and effective alternative to multiple lower dose iron sucrose infusions in NDD-CKD patients with iron-deficiency anemia.
Source: Nephrology Dialysis Transplantation - March 27, 2014 Category: Urology & Nephrology Authors: Onken, J. E., Bregman, D. B., Harrington, R. A., Morris, D., Buerkert, J., Hamerski, D., Iftikhar, H., Mangoo-Karim, R., Martin, E. R., Martinez, C. O., Newman, G. E., Qunibi, W. Y., Ross, D. L., Singh, B., Smith, M. T., Butcher, A., Koch, T. A., Goodnoug Tags: Chronic Kidney Disease Source Type: research

Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease
Conclusions Our study confirms that FGF23 is an important cardiovascular risk factor. Two measurements of FGF23 have no added value over a single value to predict the cardiovascular outcome. This study demonstrates that, under routine clinical practice, the variability of FGF23 in 2 years' time is small. Concomitantly, this study showed no benefit of consecutive FGF23 testing for estimating the risk of a clinical event in an individual patient.
Source: Nephrology Dialysis Transplantation - January 10, 2014 Category: Urology & Nephrology Authors: Bouma-de Krijger, A., Bots, M. L., Vervloet, M. G., Blankestijn, P. J., ter Wee, P. W., van Zuilen, A. D., Wetzels, J. F. Tags: Chronic Kidney Disease Source Type: research

Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study
Conclusions: In a cohort of participants with CKD, low serum bicarbonate level was an independent risk factor for kidney disease progression, particularly for participants with preserved kidney function. The risk of heart failure was higher at the upper extreme of serum bicarbonate levels. There was no association between serum bicarbonate level and all-cause mortality or atherosclerotic events.
Source: American Journal of Kidney Diseases - March 13, 2013 Category: Urology & Nephrology Authors: Mirela Dobre, Wei Yang, Jing Chen, Paul Drawz, L. Lee Hamm, Edward Horwitz, Thomas Hostetter, Bernard Jaar, Claudia M. Lora, Lisa Nessel, Akinlolu Ojo, Julia Scialla, Susan Steigerwalt, Valerie Teal, Myles Wolf, Mahboob Rahman, CRIC Investigators Tags: Pathogenesis and Treatment of Kidney Disease Source Type: research